SOCS-3 Activators
SOCS-3, or suppressor of cytokine signaling 3, is a key regulator of cytokine signaling pathways, particularly those mediated by the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Functionally, SOCS-3 acts as a negative feedback regulator, dampening cytokine signaling by inhibiting the activity of JAK kinases and/or targeting cytokine receptors for degradation. Through its inhibitory actions, SOCS-3 modulates immune responses, inflammation, and various physiological processes, ensuring proper regulation of cytokine-mediated signaling cascades. Additionally, SOCS-3 has been implicated in the regulation of insulin signaling, lipid metabolism, and neuronal function, highlighting its diverse roles beyond immune regulation.
The activation of SOCS-3 involves intricate regulatory mechanisms that are often initiated in response to cytokine stimulation or other extracellular cues. One major mechanism of SOCS-3 activation is through cytokine-induced signaling events that lead to the transcriptional upregulation of SOCS-3 expression. Cytokines such as interleukin-6 (IL-6), interleukin-10 (IL-10), and interferons (IFNs) have been shown to induce SOCS-3 expression through activation of JAK/STAT signaling pathways. Once synthesized, SOCS-3 proteins can exert their inhibitory effects through multiple mechanisms, including direct inhibition of JAK kinases via their Src homology 2 (SH2) domain or by targeting cytokine receptors for ubiquitination and proteasomal degradation. Moreover, SOCS-3 activity can be regulated by post-translational modifications such as phosphorylation, which modulate its stability, subcellular localization, and interactions with target proteins. Overall, the activation of SOCS-3 represents a crucial negative feedback mechanism that ensures tight regulation of cytokine signaling pathways and maintains immune homeostasis and cellular function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Nilotinib, an approved tyrosine kinase inhibitor, indirectly activates SOCS-3 by targeting the JAK/STAT pathway. By inhibiting the BCR-ABL fusion protein, Nilotinib disrupts aberrant signaling, leading to increased SOCS-3 expression. This compound's impact on the JAK/STAT pathway provides insights into the crosstalk between kinase inhibition and SOCS-3 activation, offering a potential avenue for modulating SOCS-3 levels in disease contexts. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG490 is a JAK2 inhibitor that indirectly activates SOCS-3 by suppressing the JAK/STAT signaling pathway. Through the inhibition of JAK2, AG490 disrupts the downstream signaling cascade, leading to enhanced SOCS-3 expression. This compound's specific targeting of JAK2 sheds light on the intricate regulatory mechanisms influencing SOCS-3 levels and its potential as a modulator of JAK/STAT-mediated cellular responses. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin, a natural polyphenol, indirectly activates SOCS-3 by modulating the STAT3 signaling pathway. By inhibiting STAT3 phosphorylation, Curcumin disrupts the signaling cascade, leading to increased SOCS-3 expression. This compound's natural origin and impact on STAT3 provide a unique perspective on the potential regulation of SOCS-3 in the context of inflammatory and oncogenic pathways. | ||||||
Piperlongumine | 20069-09-4 | sc-364128 | 10 mg | $107.00 | ||
Piperlongumine indirectly activates SOCS-3 by inhibiting STAT3 phosphorylation, disrupting the STAT3 signaling pathway. This natural compound's impact on STAT3 provides a potential mechanism for enhancing SOCS-3 expression. Piperlongumine's ability to modulate intracellular signaling pathways offers insights into the complex network of regulatory elements influencing SOCS-3 levels and its potential implications in cellular homeostasis. | ||||||
Cyt387 | 1056634-68-4 | sc-364733 sc-364733A | 10 mg 50 mg | $214.00 $612.00 | 2 | |
Momelotinib is a JAK1/2 inhibitor that indirectly activates SOCS-3 by targeting the JAK/STAT pathway. Through the inhibition of JAK1 and JAK2, Momelotinib disrupts aberrant signaling, leading to increased SOCS-3 expression. This compound's dual inhibition of JAK1/2 highlights its potential as a modulator of SOCS-3 levels in the context of JAK/STAT-mediated cellular responses. | ||||||
Cucurbitacin I | 2222-07-3 | sc-203010 | 1 mg | $250.00 | 9 | |
Cucurbitacin I indirectly activates SOCS-3 by inhibiting STAT3 phosphorylation, disrupting the STAT3 signaling pathway. This natural compound's impact on STAT3 provides a potential mechanism for enhancing SOCS-3 expression. Cucurbitacin I's ability to modulate intracellular signaling pathways offers insights into the complex network of regulatory elements influencing SOCS-3 levels and its potential implications in cellular homeostasis. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
S3I-201 is a STAT3 inhibitor that indirectly activates SOCS-3 by suppressing STAT3 phosphorylation. Through the inhibition of STAT3, S3I-201 disrupts the signaling cascade, leading to increased SOCS-3 expression. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK1/2 inhibitor, indirectly activates SOCS-3 by targeting the JAK/STAT pathway. Through the inhibition of JAK1 and JAK2, Ruxolitinib disrupts aberrant signaling, leading to increased SOCS-3 expression. This approved compound's impact on the JAK/STAT pathway provides insights into the crosstalk between kinase inhibition and SOCS-3 activation, offering a potential avenue for modulating SOCS-3 levels in disease contexts. | ||||||
Cryptotanshinone | 35825-57-1 | sc-280649 | 10 mg | $119.00 | 1 | |
Cryptotanshinone indirectly activates SOCS-3 by inhibiting STAT3 phosphorylation, disrupting the STAT3 signaling pathway. This natural compound's impact on STAT3 provides a potential mechanism for enhancing SOCS-3 expression. Cryptotanshinone's ability to modulate intracellular signaling pathways offers insights into the complex network of regulatory elements influencing SOCS-3 levels and it | ||||||